BONY EFFECTS OF TRANSIENT NONSKELETAL ILLNESS

描述(改编自申请者摘要)：本项目旨在 量化骨质疏松症发作所造成的骨丢失程度和时间进程 一种与卧床休息和分解代谢有关的暂时性疾病 影响。基本的假说是，骨丢失的恢复 这些情况往往是不完整的，特别是在关键地区 比如脊椎和臀部。如果是真的，这将意味着 与年龄相关的骨丢失是一种间歇性现象，与疾病和/或 固定，而不是连续和无情的。这一发现 将为预防骨质疏松症提供更多的机会。 作为各种分解代谢发作的替代者，调查人员 将使用常规的、选择性的腹部或盆腔手术 个人年龄在55-70岁之间。他们将用DEXA测量骨量。 150人的脊柱和髋关节在手术前，术后4-8周， 然后在4个月、8个月和12个月时量化和描述 在这种情况下，骨头会丢失。他们还将测量各种不同的 可能会修改协变量，如临时残疾程度、案例 摄入量、激素治疗、维生素D状况、年龄和生活方式因素 它们可能可信地影响骨丢失的程度或程度 恢复。他们将比较手术后不同时间点的降幅。 每名女性的基线值，并将比较 12个月，年龄和雌激素匹配的非手术对照组 替代治疗，并在12个月的间隔内测量两次。

DESCRIPTION (Adapted from the Applicant's Abstract): This project seeks to quantify the extent and time course of the bone loss produced by episodes of temporary illness of a sort associated with bed rest and catabolic influences. The underlying hypothesis is that recovery of bone lost under these circumstances is often incomplete, particularly in critical regions such as the spine and hip. If true, this would mean that some portion of age-related bone loss is a punctuated phenomenon, related to illness and/or immobilization, rather than being continuous and inexorable. This finding would open up additional opportunities for osteoporosis prevention. As a surrogate for a wide variety of catabolic episodes, the investigators will use routine, elective abdominal or pelvic surgery performed on individuals 55-70 years of age. They will measure bone mass by DEXA at spine and hip in 150 individuals before surgery, at 4-8 weeks post surgery, and then at 4, 8, and 12 months, to quantify and characterize the extent of bone lost under these circumstances. They will also measure various potentially modifying covariates, such as degree of temporary disability, Ca intake, hormonal therapy, vitamin D status, age, and life-style factors, any of which might plausibly influence extent of bone loss or degree of recovery. They will compare decreases at various time points after surgery to baseline values in each woman and will compare mean bone mass changes at 12 months with a non-operated control group matched for age and estrogen replacement therapy and measured twice across a 12-month interval.